NeoGenomics, Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of NeoGenomics, Inc. (NASDAQ: NEO) resulting from allegations that NeoGenomics may have issued materially misleading business information to the investing public.

If you purchased NeoGenomics securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased NeoGenomics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On July 31, 2023, Natera, Inc. (“Natera”), announced it had sued NeoGenomics in federal court, alleging that the NeoGenomics’ cancer test, the RaDaR molecular residual disease assay, infringed Natera’s patents.

Then, on December 27, 2023, Natera announced that the federal court had issued a preliminary injunction, effective immediately, barring NeoGenomics from making, using, selling, or promoting the RaDaR test, but that NeoGenomics may continue to offer RaDaR to existing patients and for clinical trials, studies, or projects that have been approved or in progress.

On December 28, 2023, NeoGenomics issued a press release, stating it would “appeal the preliminary injunction.”

On this news, NeoGenomics’ stock price fell $3.71 per share, or 18%, to close at $16.79 per share on December 28, 2023.

公司名称: NeoGenomics, Inc.
股票代号: NEO
集体诉讼期: N/A
法院: N/A


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。